• news.cision.com/
  • Episurf/
  • European multicentre study initiated for 5 years’ follow-up of Episealer® Talus patients

European multicentre study initiated for 5 years’ follow-up of Episealer® Talus patients

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces the initiation of a prospective investigator-initiated European multicentre study with 5 years’ follow-up of 25 Episealer® Talus patients. The study is initiated by Prof. Niek van Dijk from FIFA Medical Center of Excellence, Madrid, Spain and surgeries will be performed in a number of European countries. The patients in the study will be followed up over 5 years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score (FAOS) and EQ-5D-5L which is an instrument used for evaluation of life quality. Interim results from 2 years’ follow-up are scheduled to be submitted for publication. The first clinic to enroll patients in the study is Arcademy Clinic at Sophiahemmet, Stockholm, Sweden, lead of MD, PhD Jouko Kivioja who was also the first Episealer® Talus user in Scandinavia. Episealer® Talus is Episurf Medical’s CE marked joint implant intended for treatment of osteochondral ankle lesions.  

“I am pleased with this study design and it is important to gather clinical data for this promising technology", says Prof. Niek van Dijk.

“Robust clinical evidence is very important for us at Episurf and we are happy that a user group lead by Prof. Niek van Dijk decided to take this initiative”, says Pål Ryfors, CEO Episurf Medical. 

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:45 CEST on 22 July 2021.